Literature DB >> 9883317

Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity.

E Robak1, A Sysa-Jedrzejewska, B Dziankowska, D Torzecka, K Chojnowski, T Robak.   

Abstract

We investigated serum level of interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) using an enzyme-linked immunosorbent assay (ELISA) in 59 patients with systemic lupus erythematosus (SLE) and 16 healthy controls. We examined a possible association between serum levels of these cytokines and SLE activity, as well as correlation between IFN-gamma concentration and the level of TNF-alpha and IL-6 and also IL-6 and TNF-alpha. TNF-alpha and IL-6 were detectable in all 59 patients and normal individuals and their level was significantly higher in SLE patients than in the control group (p < 0.001 and p < 0.02, respectively). In contrast IFN-gamma was detectable in 23 (39%) patients and in only 3 (20%) healthy individuals. We found positive correlation between serum concentration of TNF-alpha and IL-6 with SLE activity and no such correlation with IFN-gamma. We also observed positive correlation between serum levels of IFN-gamma and TNF-alpha, IFN-gamma and IL-6 as well as TNF-alpha and IL-6. In conclusion, an increase in the serum levels of TNF-alpha and IL-6 may be useful markers for SLE activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9883317

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  7 in total

1.  The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus.

Authors:  Kathleen E Sullivan; April Suriano; Kelly Dietzmann; Janice Lin; Daniel Goldman; Michelle A Petri
Journal:  Clin Immunol       Date:  2007-02-05       Impact factor: 3.969

2.  Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.

Authors:  Michael Murphy; Goutham Pattabiraman; Tissa T Manavalan; Andrei E Medvedev
Journal:  Eur J Immunol       Date:  2017-03-31       Impact factor: 5.532

3.  Cytokine-induced monocyte characteristics in SLE.

Authors:  Zhe Zhang; Kelly Maurer; Juan C Perin; Li Song; Kathleen E Sullivan
Journal:  J Biomed Biotechnol       Date:  2010-06-24

4.  Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis.

Authors:  Sawsan J Hayat; Sukhbir S Uppal; M R Narayanan Nampoory; Kaivilayil V Johny; Ramkumar Gupta; Mohammed Al-Oun
Journal:  Clin Rheumatol       Date:  2006-03-25       Impact factor: 3.650

5.  Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells.

Authors:  Sangeeta Sule; Antony Rosen; Michelle Petri; Ehtisham Akhter; Felipe Andrade
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

6.  Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation.

Authors:  Undurti N Das
Journal:  J Inflamm Res       Date:  2010-12-02

7.  The effect of long-term glucocorticoids on bone metabolism in systemic lupus erythematosus patients: the prevalence of its anti-inflammatory action upon bone resorption.

Authors:  Izabela Korczowska; Anna Olewicz-Gawlik; Paweł Hrycaj; Jan Lacki
Journal:  Yale J Biol Med       Date:  2003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.